Revascularization in renal artery stenosis.

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Interventional Cardiology

Background:

• Atherosclerosis is the primary cause of renal artery stenosis (RAS), leading to hypertension and kidney dysfunction.
• Medical management with antihypertensives, statins, and aspirin has improved outcomes for atherosclerotic RAS.
• Revascularization is considered for specific scenarios like renal function preservation and refractory hypertension.

Purpose of the Study:

• To evaluate the efficacy of revascularization versus medical therapy for atherosclerotic renal artery stenosis.
• To analyze the impact of revascularization on blood pressure control and renal function.
• To review the current evidence regarding the benefits of intervention in managing RAS.

Main Methods:

• Review of observational studies and randomized controlled trials (RCTs) on renal artery stenosis management.
• Comparison of outcomes between medical therapy alone and revascularization plus medical therapy.
• Analysis of data on blood pressure, renal function, cardiovascular events, and mortality.

Main Results:

• Observational studies suggest revascularization benefits blood pressure and renal function.
• RCTs have not consistently reproduced these benefits, showing similar outcomes to medical therapy alone.
• The impact of revascularization on heart failure and major cardiovascular events remains largely untested in RCTs.

Conclusions:

• The efficacy of revascularization for atherosclerotic RAS compared to medical therapy alone is controversial.
• Current guidelines suggest revascularization for resistant hypertension, but RCT evidence is lacking.
• Further research is needed to clarify the role of revascularization in specific patient populations with RAS.